Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VIVS VivoSim Labs Inc.
- Stocks
- Healthcare
- NASDAQ: VIVS
Price (delayed)
$1.94
Market cap
$2.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.2
Enterprise value
$2.83M
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are
Highlights
The EPS has soared by 61% year-on-year and by 20% since the previous quarter
The net income is up by 35% year-on-year
VIVS's gross profit has dropped by 52% year-on-year but it is up by 17% since the previous quarter
The revenue has contracted by 50% YoY but it has grown by 18% from the previous quarter
The equity has dropped by 94% year-on-year and by 90% since the previous quarter
VIVS's quick ratio has plunged by 86% YoY and by 68% from the previous quarter
Key stats
What are the main financial stats of VIVS
Market
Valuations
Earnings
Shares outstanding
1.45M
Market cap
$2.82M
Enterprise value
$2.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.82
Price to sales (P/S)
23.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.24
Revenue
$122,000
Gross profit
$117,000
Operating income
-$12.56M
Net income
-$12.39M
EBIT
-$12.38M
EBITDA
-$12.1M
Free cash flow
-$10.11M
Per share
Balance sheet
Liquidity
EPS
-$10.2
EPS diluted
-$10.2
Free cash flow per share
-$6.72
Book value per share
$0.28
Revenue per share
$0.08
TBVPS
$2.55
Total assets
$3.84M
Total liabilities
$3.48M
Debt
$1.32M
Equity
$364,000
Working capital
-$837,000
Debt to equity
3.62
Current ratio
0.72
Quick ratio
0.45
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
-9,919.7%
Gross margin
95.9%
Net margin
-10,151.6%
Operating margin
-10,293.4%
Return on assets
-187.5%
Return on equity
-346.3%
Return on invested capital
-567%
Return on capital employed
-1,364.7%
Return on sales
-10,145.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIVS stock price
How has the VivoSim Labs stock price performed over time
Intraday
3.19%
1 week
-0.51%
1 month
16.17%
1 year
-83.67%
YTD
-64.86%
QTD
-13.39%
Financial performance
How have VivoSim Labs's revenue and profit performed over time
Revenue
$122,000
Gross profit
$117,000
Operating income
-$12.56M
Net income
-$12.39M
Gross margin
95.9%
Net margin
-10,151.6%
VIVS's gross profit has dropped by 52% year-on-year but it is up by 17% since the previous quarter
The revenue has contracted by 50% YoY but it has grown by 18% from the previous quarter
The operating income has grown by 36% YoY
The net income is up by 35% year-on-year
Price vs fundamentals
How does VIVS's price correlate with its fundamentals
Growth
What is VivoSim Labs's growth rate over time
Valuation
What is VivoSim Labs stock price valuation
P/E
N/A
P/B
6.82
P/S
23.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.24
The EPS has soared by 61% year-on-year and by 20% since the previous quarter
The stock's price to book (P/B) is 153% more than its 5-year quarterly average of 2.7 and 4.9% more than its last 4 quarters average of 6.5
The equity has dropped by 94% year-on-year and by 90% since the previous quarter
The P/S is 76% below the last 4 quarters average of 99.1
The revenue has contracted by 50% YoY but it has grown by 18% from the previous quarter
Efficiency
How efficient is VivoSim Labs business performance
The ROE has plunged by 89% YoY and by 39% from the previous quarter
VIVS's return on assets is down by 35% year-on-year and by 18% since the previous quarter
The ROS has declined by 29% year-on-year but it has increased by 17% since the previous quarter
VIVS's return on invested capital is down by 25% since the previous quarter
Dividends
What is VIVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIVS.
Financial health
How did VivoSim Labs financials performed over time
The total assets is 10% greater than the total liabilities
VIVS's quick ratio has plunged by 86% YoY and by 68% from the previous quarter
VIVS's current ratio has shrunk by 80% YoY and by 64% QoQ
The equity has dropped by 94% year-on-year and by 90% since the previous quarter
VIVS's debt is down by 15% since the previous quarter and by 12% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.